RxDoctor Payments DataLook up a doctor →

Praveen Rao, MD

Clinical Cardiac Electrophysiology · Dallas, TXNPI 1043448285

Payments from drug & device makers

$135,002in general payments, 2019–2025

Across 548 payments — averaging $246.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$87K
  • Medtronic$32K
  • Boston Scientific$7K
  • Biosense Webster, Inc.$5K
  • Medical Device Business Services, Inc.$2K
  • AOP Health US, LLC$430
  • plus $2K from 21 others
$200in research payments, 2019–2025

Across 1 payment — averaging $200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$200

What the payments were for

  • Consulting fees$35,25253%
  • Speaking & faculty fees$6,50010%
  • Travel & lodging$10,87016%
  • Food & beverage$14,36321%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,002 in reported general payments places this provider in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$386,364
Medicare patients
2,095
Services billed
5,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban358$346,120
XareltoRivaroxaban63$74,860
EntrestoSacubitril/Valsartan12$11,676
Flecainide Acetate129$6,221
Dofetilide23$5,987
Metoprolol Succinate153$2,203
SotalolSotalol Hcl51$1,016
Amiodarone Hcl70$955
ClopidogrelClopidogrel Bisulfate62$787
Potassium Chloride14$352
Atorvastatin Calcium21$252
Losartan Potassium15$144
Metoprolol Tartrate22$130
Carvedilol19$112
Spironolactone16$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$346,120358 claims
Johnson & JohnsonXarelto$56$74,86063 claims
NovartisEntresto$272$11,67612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →